Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | MicrobiomeTrials← Back to trialsNCT05569772
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-09-14Est. Completion: 2029-06
Enrollment target: 252 participants Locations- AZORG, Aalst, Belgium
- UZA, Antwerp, Belgium
- ZAS, Antwerp, Belgium
- AZ St Jan Brugge, Bruges, Belgium
- Erasme, Brussels, Belgium
- UZ Brussel, Brussels, Belgium
- Jan Yperman, Ieper, Belgium
- AZ Groeninge Kortrijk, Kortrijk, Belgium
- UZ Leuven, Leuven, Belgium
- CHU de Liège, Liège, Belgium
- Centre Hospitalier Mouscron, Mouscron, Belgium
- Vitaz, Sint-Niklaas, Belgium
- AZ Turnhout, Turnhout, Belgium
Other microbiome trials you might be interested in
Pre-Gestational DiabetesType2diabetesPregnancy in DiabeticPregnancy, High RiskGestational DiabetesGestational Diabetes Mellitus in the Puerperium
DIP : To conduct a pragmatic, non-blinded randomized controlled trial (pRCT) of immediate in-patient postpartum OGTT pri…
Columbus, United StatesEst. completion Jun 30, 2026
Pre DiabetesPostpartum Disorder
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women wit…
Baton Rouge, United States
Est. completion Jan 1, 2026